The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: A pilot study.
about
Pharmacotherapy for stimulant-related disordersThe role of guanfacine as a therapeutic agent to address stress-related pathophysiology in cocaine-dependent individuals.Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications.Psychostimulant addiction treatment.Psychostimulants affect dopamine transmission through both dopamine transporter-dependent and independent mechanisms.Role of the α1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial.Evaluation of the dopamine β-hydroxylase (DβH) inhibitor nepicastat in participants who meet criteria for cocaine use disorder.Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation.Adrenaline rush: the role of adrenergic receptors in stimulant-induced behaviorsDrugs currently in Phase II clinical trials for cocaine addiction.Investigational therapies for the pharmacological treatment of alcoholism.Emerging drugs for the treatment of cocaine use disorder: a review of neurobiological targets and pharmacotherapy.Novel interventions to prevent HIV and HCV among persons who inject drugs.Norepinephrine regulates cocaine-primed reinstatement via α1-adrenergic receptors in the medial prefrontal cortex.Psychostimulant drugs for cocaine dependence.Effects of prazosin and doxazosin on yohimbine-induced reinstatement of alcohol seeking in rats.Effect of doxazosin on stress reactivity and the ability to resist smoking.Noradrenergic signaling in the VTA modulates cocaine craving.Carvedilol does not reduce cocaine use in methadone-maintained cocaine users.Pharmacogenetics of Dopamine β-Hydroxylase in cocaine dependence therapy with doxazosin.
P2860
Q26829186-7E1B6800-B2EF-486B-85E0-B587D0785603Q33598487-3C829B93-CF9C-446A-95C4-CFFE17206AF1Q35576598-8E687F9B-6B3F-4320-AB0B-C723F94DA832Q35915231-49473062-507B-4CA9-8910-19FEF825E9EDQ36144909-C90A978D-6FA7-473D-BB32-83277423780FQ36342939-AEF80455-D8F1-45B4-BC9E-E43F14A05D93Q36650526-603CD108-E6FF-402C-A2D2-10C03077DB64Q37282486-193F114F-47D9-40AE-A7B2-8AD53B3E0A21Q37663376-C32F37BB-CE82-4CEA-8AE4-C58B47B1BC87Q38207705-350F3B19-61F6-44DC-9C8A-89E431EC37F4Q38244035-0F405965-015D-45EB-BAA7-98BCA7FB8017Q38271498-BC538873-4478-4260-BB97-95823CCA8C77Q38318678-EB161883-B1A2-4624-8447-DA3B34989F4BQ38845514-94DA8E81-D631-4031-A3CA-5A6C0F0635EAQ38964799-5F1989AB-E86B-48B3-8A76-55F76C43CE87Q39884301-A2255122-38C7-4AE0-8800-6F10DE61A46FQ40229079-C0F8FE53-5E90-4DC6-B5B8-9FDD995C2D8AQ48246919-61A73302-E49B-4AAE-8E64-FDCDFDF02732Q49200588-6663A8FF-619D-48A2-B278-FA7FA47813A2Q51745354-B9543E02-4EB1-4177-8C55-BEAC45A659A1
P2860
The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: A pilot study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
The alpha-1 adrenergic antagon ...... ine dependence: A pilot study.
@en
type
label
The alpha-1 adrenergic antagon ...... ine dependence: A pilot study.
@en
prefLabel
The alpha-1 adrenergic antagon ...... ine dependence: A pilot study.
@en
P2093
P2860
P1476
The alpha-1 adrenergic antagon ...... ine dependence: A pilot study.
@en
P2093
J A Lindsay
T R Kosten
P2860
P356
10.1016/J.DRUGALCDEP.2012.11.021
P577
2013-01-08T00:00:00Z